Interferon alpha-2b biosimilar - Biosidus

Drug Profile

Interferon alpha-2b biosimilar - Biosidus

Alternative Names: Bioferon; Biosidus interferon alpha 2b; Citopheron™; Ganapar™; Inter 2B™; Zavinex™

Latest Information Update: 20 Sep 2013

Price : $50

At a glance

  • Originator Biosidus S.A.
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Cancer; Hepatitis B; Hepatitis C; Kaposi's sarcoma

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 29 Apr 2013 Launched for Cancer in Thailand (Parenteral)
  • 29 Apr 2013 Launched for Hepatitis B in Thailand (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top